<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-W6FBDQ3C</identifier><date>2025</date><creator>Božič, Tim</creator><creator>Čemažar, Maja</creator><creator>De Marco, Ario</creator><creator>Lampreht Tratar, Urša</creator><creator>Pišljar, Živa</creator><creator>Štrancar, Urša</creator><relation>documents/doc/W/URN_NBN_SI_doc-W6FBDQ3C_001.pdf</relation><relation>documents/doc/W/URN_NBN_SI_doc-W6FBDQ3C_001.txt</relation><format format_type="extent">Str. 107</format><identifier identifier_type="COBISSID_HOST">254512899</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-W6FBDQ3C</identifier><language>slv</language><publisher publisher_location="Ljubljana">Onkološki inštitut</publisher><publisher publisher_location="Ljubljana">Združenje za radioterapijo in onkologijo pri Slovenskem zdravniškem društvu</publisher><source>2. slovenski znanstveni simpozij o raziskavah raka</source><rights>InC</rights><subject language_type_id="slv">diagnostična dejavnost</subject><subject language_type_id="slv">krvni raki</subject><subject language_type_id="slv">onkologija</subject><title>Recombinant cd30 nanobodies as robust and costeffective alternatives to conventional antibodies for diagnostics of hematologic malignancies</title></Record>